- Spurred by deep cuts and M&A activity, H1 layoffs could oust 14,000+ in biopharmaTakeda’s cuts will go the deepest, affecting over 4,700 employees. Layoffs tied to M&A activity include BioNTech letting go of around 800 people at CureVac.BioSpace · 11d ago↗ source
- Recon: Lilly to buy psychedelic developer AtaiBeckley for up to $3.8B; FDA approves Merck’s novel cholesterol drug<p>Welcome to Regulatory Reconnaissance, your regulatory news and intelligence briefing.</p>raps · 11d ago↗ source
- Euro Roundup: EMA posts guidance on preventing microbial contamination of non-sterile products<p>The European Medicines Agency (EMA) has released guidance on technical and organizational measures that companies should consider to prevent microbial contamination of non-sterile products.</p>